Pfizer's drug combines an acetyl-coA carboxylase (ACC) inhibitor with a diacylglycerol O-acyltransferase 2 (DGAT2) inhibitor. The problem with ACC inhibitors is they greatly increase blood lipids which leads to a large increase in cholesterol. Not a good thing with heart disease. the addition of DGAT2 supposedly limits that increase in blood lipids.

Pfizer had an earlier version of their DGAT2 inhibitor but shelved it even though it showed a 38% reduction in liver fat because they said it wasn't a good long term solution. My guess is that it had the same blood lipid problem.
Leronlimab converting white fat to brown fat and being protectant against heart disease should not have that problem.

Gilead had an ACC inhibitor which they also shelved because it reduced fat but not scarring without worsening of NASH.

https://endpts.com/pfizers-retired-nash-drug-...2-pathway/

https://www.fiercebiotech.com/biotech/another...ps-phase-2